ArticleMediators of inflammation2013
Eosinophil-derived neurotoxin is elevated in patients with amyotrophic lateral sclerosis.
Article in Mediators of inflammation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Trial
- Allergic disease as a risk factor for Parkinson's disease: a possible role of eosinophil.NPJ Parkinson's disease · 2026Article
- Peripheral immunity involvement in the cognitive impairment of sporadic amyotrophic lateral sclerosis.Frontiers in neurology · 2024Article
- Genome-wide analyses identify NEAT1 as genetic modifier of age at onset of amyotrophic lateral sclerosis.Molecular neurodegeneration · 2023Article
- Intracellular DAMPs in Neurodegeneration and Their Role in Clinical Therapeutics.Molecular neurobiology · 2023Review
- Eosinophil: An innate immune cell with anti-filarial vaccine and biomarker potential.Health science reports · 2023Article
- Review
- Biomarkers and molecular mechanisms of Amyotrophic Lateral Sclerosis.AIMS neuroscience · 2022Review
- Imaging immunological processes from blood to brain in amyotrophic lateral sclerosis.Clinical and experimental immunology · 2021Review
- Pharmacophore-based discovery of 2-(phenylamino)aceto-hydrazides as potent eosinophil peroxidase (EPO) inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2018Article
- Temporospatial Analysis and New Players in the Immunology of Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2018Review
- Endomyocardial involvement in asymptomatic sub-Saharan immigrants with helminth-related eosinophilia.PLoS neglected tropical diseases · 2017Article
- Immune-mediated processes in neurodegeneration: where do we stand?Journal of neurology · 2016Review
- Blood biomarkers for amyotrophic lateral sclerosis: myth or reality?BioMed research international · 2014Review
- Cholesterol selectively regulates IL-5 induced mitogen activated protein kinase signaling in human eosinophils.PloS one · 2014Article
- Basic amino acid residues of human eosinophil derived neurotoxin essential for glycosaminoglycan binding.International journal of molecular sciences · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by loss of motor neurons in the brainstem, motor cortex, and spinal cord. Oxidative stress and neuroinflammation have been implicated in the pathophysiology of ALS. Members of the family of damage-associated molecular patterns, including reactive oxygen species, high-mobility group box 1, and eosinophil-derived neurotoxin (EDN), may participate in pathological conditions. In this study, we aim to discover new biomarker for detecting ALS. MATERIALS AND
methodsWe examined 44 patients with ALS, 41 patients with Alzheimer's disease, 41 patients with Parkinson's disease, and 44 healthy controls. The concentration of serum EDN was measured using an enzyme-linked immunosorbent assay.
resultsEDN levels were significantly increased 2.17-fold in the serum of patients with ALS as compared with healthy controls (P < 0.05). No correlation between the levels of serum EDN and various clinical parameters of ALS was found. Moreover, the levels of serum EDN in patients with Parkinson's disease and Alzheimer's disease and healthy controls were similar.
conclusionA higher level of serum EDN was found specifically in patients with ALS, indicating that EDN may participate in the pathophysiology of ALS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.